Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility

From General Health to Occupational Exposure

The legacy of general health and science information, as exemplified by archives such as the Immunodeficiency Foundation, has long provided a foundational understanding of human biology and disease. This heritage emphasizes the importance of immune system integrity and the broad principles of host defense, offering a baseline for evaluating how external factors may disrupt normal physiological processes. Within this context, the transition from general health awareness to specific occupational exposure concerns requires a careful pivot. In mass production settings, workers may encounter a range of chemical and biological agents that could theoretically interact with immune function. One such agent of interest is Avelumab, a therapeutic monoclonal antibody used in oncology. While its primary role is immunomodulatory, the question of whether occupational exposure to Avelumab could plausibly influence the risk of developing Merkel Cell Carcinoma warrants examination. This consideration moves the discussion from a general health framework into a focused occupational exposure scenario, where the biological plausibility of such a relationship must be assessed without invoking specific mechanistic claims. The shift thus reframes the legacy of general health knowledge into a targeted inquiry about workplace safety and potential long-term health outcomes.

Biological Plausibility of Avelumab-Induced Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). However, the relationship between avelumab and MCC causation requires careful examination of biological plausibility, clinical presentation, and risk considerations. MCC is a rare skin cancer with neuroendocrine differentiation, and approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). Despite these benefits, approximately 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab, as an immune checkpoint inhibitor, is known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781). For example, a case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC has been reported, managed with corticosteroids while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). The biological plausibility of avelumab causing or contributing to MCC is not supported by the available evidence. Instead, avelumab is used as a therapeutic agent for existing MCC, not as a causative factor. The evidence indicates that avelumab is an approved treatment for metastatic MCC, and its mechanism of action—blocking PD-L1 to enhance T-cell responses—is intended to combat the cancer (https://pubmed.ncbi.nlm.nih.gov/29799096). In patients with avelumab-refractory MCC, subsequent treatment with ipilimumab plus nivolumab has shown responses in some cases, suggesting that avelumab does not induce MCC but rather that some tumors may evade immune control despite PD-L1 inhibition (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). The timeline between avelumab exposure and any documented harm typically involves irAEs occurring during treatment, not the development of de novo MCC. For instance, irAEs such as sarcoidosis reactivation have been reported during avelumab therapy, but these are distinct from MCC causation (https://pubmed.ncbi.nlm.nih.gov/31543781). Risk considerations for affected patients include the adequacy of warnings regarding avelumab and MCC. The prescribing information for avelumab includes warnings about immune-related adverse events, which are common with checkpoint inhibitors, but there is no evidence suggesting that avelumab causes MCC. The drug is specifically indicated for treating metastatic MCC, and its use is based on clinical trials demonstrating efficacy in this population (https://pubmed.ncbi.nlm.nih.gov/29799096). Causation-related considerations for patients who develop MCC after avelumab exposure would need to account for the natural history of the disease, which often presents before or during treatment. The timeline between exposure and harm is typically measured in weeks to months for irAEs, but for MCC itself, the disease is pre-existing or arises independently of avelumab therapy. In summary, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma; rather, avelumab is a treatment for this condition, and any harms are related to immune-related adverse events, not causation of the cancer itself.

Evidence and Risk Context

The available evidence consistently demonstrates that avelumab is an effective treatment for metastatic Merkel cell carcinoma, not a causative agent. The drug's mechanism of action—blocking PD-L1 to enhance anti-tumor immune responses—is directly opposed to carcinogenesis. Clinical trials and post-marketing surveillance have not identified signals suggesting that avelumab increases the risk of developing MCC. Instead, the primary risks associated with avelumab are immune-related adverse events, which are manageable and distinct from cancer causation. For workers with occupational exposure to avelumab, the theoretical risk of developing MCC is not supported by biological plausibility or epidemiological data. The known causes of MCC—Merkel cell polyomavirus and UV-induced mutations—are unrelated to avelumab's pharmacodynamics. Therefore, any claim of avelumab causing MCC would contradict established scientific understanding.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, avelumab is not known to cause Merkel cell carcinoma. It is an FDA-approved treatment for metastatic Merkel cell carcinoma. The drug works by blocking PD-L1 to enhance the immune system's ability to fight cancer cells. Available evidence from clinical trials and post-marketing surveillance does not support a causal link between avelumab and the development of MCC.

What are the known risks of avelumab?

The primary risks of avelumab are immune-related adverse events (irAEs), such as pneumonitis, colitis, hepatitis, endocrinopathies, and sarcoidosis reactivation. These occur due to overactivation of the immune system. The prescribing information includes warnings about these events, but there is no evidence that avelumab causes Merkel cell carcinoma.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.